Archive for September, 2001

September 20, 2001

Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

.   .   

Landmark randomized controlled trial which showed that, compared with amlodipine, irbesartan reduced the primary composite end point of a doubling of the base-line serum creatinine concentration, the development of end-stage renal disease, or death from any cause in patients with diabetic nephropathy.

1 Comment Posted in Chronic Kidney Disease, Diabetes, RAS Blockade
September 20, 2001

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

.   .   

A landmark randomized controlled trial which showed that, compared to placebo, losartan reduced the incidence of a doubling of the serum creatinine concentration and end-stage renal disease.

Comments Off on Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy Posted in Chronic Kidney Disease, Diabetes, RAS Blockade